Endonovo Therapeutics (OTCQB: ENDV), a commercial-stage developer of noninvasive Electroceutical® therapeutic devices, has completed clinical trials and is currently expanding commercialization of its SofPulse® device that delivers pulsed electromagnetic frequencies for pain management. An article discussing the company reads, “In August, Endonovo announced its Q2 financial results, showing growth in both revenue and gross profits. However, since the economic potential for a safe, nonaddictive alternative to opioids is significant, the company’s continued progress as it reaches developmental and test milestones is clearly the key focus. Over the second quarter of 2019, the company expanded SofPulse® commercialization and announced the first commercial sales of the device for post-operative pain and edema. ‘The opioid epidemic is a major issue in society today, making SofPulse® a significant alternative to postoperative pain management. We believe we have laid the foundation for rapid growth and expansion,’ Endonovo CEO Alan Collier said in a company news release (http://ibn.fm/F4JX0).”
To view the full article, visit http://ibn.fm/3EUv0
About Endonovo Therapeutics
Endonovo Therapeutics is a commercial-stage developer of noninvasive, wearable Electroceuticals® therapeutic devices. The company’s current portfolio of commercial and clinical-stage wearable Electroceuticals® therapeutic devices addresses wound healing, pain, postsurgical pain and edema, cardiovascular disease, chronic kidney disease, and central nervous system (“CNS”) disorders including traumatic brain injury (“TBI”), acute concussions, postconcussion syndrome and multiple sclerosis. The company’s noninvasive Electroceutical® therapeutic device, SofPulse®, which uses pulsed short-wave radiofrequency at 27.12 MHz, has been FDA cleared and CE marked for the palliative treatment of soft-tissue injuries and postoperative pain and edema and has CMS national coverage for the treatment of chronic wounds. The company’s current portfolio of preclinical-stage Electroceuticals® therapeutic devices addresses chronic kidney disease, liver-disease nonalcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The company’s noninvasive, wearable Electroceuticals® therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth-factor cascades necessary for healing to occur. For more information, visit the company’s website at www.Endonovo.com.
NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.